Israel offers numerous clinical trials for adenocarcinoma, led by principal investigators like Dr. David Sarid and Dr. Ari Raphael at Sourasky Medical Center. These trials focus on advanced immunotherapies, genomic profiling, and targeted drug combinations for lung, prostate, and digestive tract cancers.
- Principal investigators. Dr. David Sarid leads active clinical trials for new systemic cancer therapies.
- Immunotherapy research. Dr. Ari Raphael conducts early-phase trials for non-small cell lung cancer treatment.
- Abdominal cancer studies. Dr. Pelles Sharon researches patient attitudes while offering advanced HIPEC and immunotherapy.
- National leadership. Prof. Dr. Ido Wolf chairs the national council overseeing malignant disease treatments.
Bookimed Expert Insight: Patients can access groundbreaking trials specifically for adenocarcinoma by targeting specialists like Dr. Ari Raphael, who leads the National Genomic Medicine Initiative. This integration of national genomics with early-phase trials at Sourasky Medical Center provides faster access to molecularly targeted therapies not yet available on the standard market.
Patient Consensus: Patients receiving treatment often find that starting with genomic profiling early helps them enter clinical trials faster. Those traveling to Israel noted that having coordinators manage tissue shipping significantly reduced their wait times for finding appropriate study groups.
